Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | PPIG | Q13427 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430486 | 0.87 | OPRM1 (0.44) | PPIDSMN1; SMN2RIPK1OPRM1OPRL1 | |
| SCHEMBL13430501 | 0.84 | PPID (0.46) | PPIDSMN1; SMN2MAPTRIPK1CTSK | |
| SCHEMBL14531434 | 0.79 | PPID (0.58) | PPIDSMN1; SMN2MAPTRIPK1CTSK | |
| SCHEMBL3225864 | 0.75 | PPID (0.48) | PPIDSMN1; SMN2MAPTRIPK1CTSK | |
| SCHEMBL1052780 | 0.73 | HDAC3 (0.53) | PPIDSMN1; SMN2ALDH1A1LMNACTSL | |
| SCHEMBL4193440 | 0.73 | CA12 (0.47) | PPIDSMN1; SMN2RIPK1OPRM1OPRL1 | |
| SCHEMBL4246502 | 0.72 | CA12 (0.46) | PPIDSMN1; SMN2RIPK1OPRM1OPRL1 | |
| SCHEMBL31248355 | 0.72 | PRSS1 (0.52) | SMN1; SMN2RIPK1ALDH1A1LMNACA12 | |
| SCHEMBL7998541 | 0.72 | ALOX5 (0.49) | PPIDSMN1; SMN2CTSKALDH1A1LTA4H | |
| SCHEMBL28131444 | 0.72 | L3MBTL1 (0.43) | PPIDSMN1; SMN2ALDH1A1LMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293743-B2 | Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells | CHOONGWAE PHARMA CORPORATION (KR) | 2012-10-23 | — | — | US | disclosed |
| US-8293743-B2 | Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells | CHOONGWAE PHARMA CORPORATION (KR) | 2012-10-23 | — | — | US | disclosed |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
| WO-2007056513-A1 | α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | INSTITUTE FOR CHEMICAL GENOMICS (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056593-A2 | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | PPID 2217/4885SMN1; SMN2 623/4885MAPT 2446/4885 |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | PPID 4027/4885SMN1; SMN2 1332/4885MAPT 4304/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | PPID 2040/4885SMN1; SMN2 3642/4885MAPT 2031/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | PPID 4026/4885SMN1; SMN2 1235/4885MAPT 4249/4885 |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | MCL1, HNF4A, THPO | PPID 1965/4885SMN1; SMN2 3380/4885MAPT 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.